Abstract:Lack of efficacy or adverse drug response are common phenomena in pharmacological therapy causing considerable morbidity and mortality. It is estimated that 20–30% of this variability in drug response stems from variations in genes encoding drug targets or factors involved in drug disposition. Leveraging such pharmacogenomic information for the preemptive identification of patients who would benefit from dose adjustments or alternative medications thus constitutes an important frontier of precision medicine. Computational methods can be used to predict the functional effects of variant of unknown significance. However, their performance on pharmacogenomic variant data has been lackluster. To overcome this limitation, we previously developed an ensemble classifier, termed APF, specifically designed for pharmacogenomic variant prediction. Here, we aimed to further improve predictions by leveraging recent key advances in the prediction of protein folding based on deep neural networks. Benchmarking of 28 variant effect predictors on 530 pharmacogenetic missense variants revealed that structural predictions using AlphaMissense were most specific, whereas APF exhibited the most balanced performance. We then developed a new tool, APF2, by optimizing algorithm parametrization of the top performing algorithms for pharmacogenomic variations and aggregating their predictions into a unified ensemble score. Importantly, APF2 provides quantitative variant effect estimates that correlate well with experimental results (R 2 = 0.91, p = 0.003) and predicts the functional impact of pharmacogenomic variants with higher accuracy than previous methods, particularly for clinically relevant variations with actionable pharmacogenomic guidelines. We furthermore demonstrate better performance (92% accuracy) on an independent test set of 146 variants across 61 pharmacogenes not used for model training or validation. Application of APF2 to population-scale sequencing data from over 800,000 individuals revealed drastic ethnogeographic differences with important implications for pharmacotherapy. We thus think that APF2 holds the potential to improve the translation of genetic information into pharmacogenetic recommendations, thereby facilitating the use of Next-Generation Sequencing data for stratified medicine.

Pervasive ancestry bias in variant effect predictors

Variant effect predictor correlation with functional assays is reflective of clinical classification performance

The Impact of Clinical and Molecular Variant Properties on Calibration and Performance of Variant Effect Prediction Tools

Understanding the heterogeneous performance of variant effect predictors across human protein-coding genes

Updated benchmarking of variant effect predictors using deep mutational scanning

Guidelines for releasing a variant effect predictor

Assessment of variant effect predictors unveils variants difficulty as a critical performance indicator

Missing genetic diversity impacts variant prioritisation for rare disorders

Toward Automatic Variant Interpretation: Discordant Genetic Interpretation Across Variant Annotations for ClinVar Pathogenic Variants

Variant Impact Predictor database (VIPdb), version 2: trends from three decades of genetic variant impact predictors

Using deep mutational scanning to benchmark variant effect predictors and identify disease mutations

Critical assessment of missense variant effect predictors on disease-relevant variant data

Variant scoring performance across selection regimes depends on variant-to-gene and gene-to-disease components

Diverse ancestral representation improves genetic intolerance metrics

Variable prediction accuracy of polygenic scores within an ancestry group

Disparities in cancer genomics by ancestry in the 100,000 Genomes Project

Efficient Utilization of Rare Variants for Detection of Disease-Related Genomic Regions

A Comparison on Predicting Functional Impact of Genomic Variants.

Characterizing the pathogenicity of genetic variants: the consequences of context

APF2: an improved ensemble method for pharmacogenomic variant effect prediction